Articles related to Pulmonology

An observational analysis reviewed 54 studies and two medical record databases with data for 1.2 million individuals, to determine how many people experienced at least 1 of the 3 self-reported Long COVID symptom clusters 3 months after infection. The results indicate a Long COVID rate of 6.2%: 3.7% for ongoing respiratory problems, 3.2% for persistent fatigue with bodily pain or mood swings, and 2.2% for cognitive problems.

Palliative care (PC) can help reduce emergency department use, hospitalizations, and symptom burden across a spectrum of diseases. To assist clinicians in keeping their expertise current, the authors reviewed and summarized the top PC articles of 2020. The analysis included 28 PC intervention trials for heart failure, chronic obstructive pulmonary disease, and dementia.

An 18-year-old man comes to you for a sports physical. He is asymptomatic, with no limitation in his exercise capacity. He has a history of exercise-induced bronchospasm for which he takes a budesonide-formoterol inhaler. He does not smoke, drink alcohol, or use any drugs. There is no family history of cardiac disease or sudden death. What’s the next appropriate test?

A quartet of current clinical trials involving first-in-class molecules and CRISPR gene editing show great promise. STELLAR investigates a fusion protein in PAH, CodeBreak 200 studies a first-in-class of KRAS inhibitor, EMERGENT-2 focuses on a new treatment for schizophrenia, and NCT04601051 studies a gene editing drug for one form of amyloidosis.

Questions run across a host of topics, and in September you can challenge yourself in mortality risk, myocardial infarction (MI), insomnia, liver cancer, lipids, and Parkinson’s disease guidelines. Each question is worth 4 points with bonuses for quick response. Speed matters in this quiz. Why not give it a try and see if you can get on the leaderboard of the Smartest Doc?

To assess short-term risk for severe cardiovascular events (excluding myocarditis and pericarditis) after COVID-19 vaccination, adults younger than 75 years hospitalized for PE, acute MI, hemorrhagic stroke, or ischemic stroke (73,325 events) were reviewed in relation to a 1st or 2nd COVID vaccine dose. No association was found between the Pfizer–BioNTech or Moderna vaccine and severe cardiovascular events. The first dose of the Oxford–AstraZeneca vaccine was associated with acute MI and PE in the second week after vaccination. An association with MI in the second week after a single dose of the Janssen vaccine could not be ruled out.